HNWAG
OVID icon

High Net Worth Advisory Group’s Ovid Therapeutics OVID Stock Holding History

High Net Worth Advisory Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,800
Closed -$6K – 711
2021
Q4 		$6K Buy
+1,800
New +$6.17K ﹤0.01% 586

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

High Net Worth Advisory Group's OVID Position: Q1 2022 in Review

High Net Worth Advisory Group sold out of Ovid Therapeutics (OVID) in Q1 2022, closing a stake of 1,800 shares — an estimated $6K sold.

High Net Worth Advisory Group first reported a position in OVID in Q4 2021 and held it in 1 quarter. The position peaked at $6K in Q4 2021. 62 funds tracked by Wall St. Rank hold OVID as of Q1 2022.

  • High Net Worth Advisory Group reported no remaining Ovid Therapeutics position as of Q1 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 1,800 Ovid Therapeutics shares in Q1 2022, an estimated $6K.
  • High Net Worth Advisory Group first reported a position in Ovid Therapeutics in Q4 2021 and held it in 1 quarter.
  • High Net Worth Advisory Group's Ovid Therapeutics position peaked at $6K in Q4 2021.
  • 62 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2022.

Based on High Net Worth Advisory Group's 13F filing for Q1 2022, filed 13 May 2022.